Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Colgate Boosts Digital Marketing Spend, Trims Product Line

This article was originally published in The Tan Sheet

Executive Summary

Colgate has 45 Facebook pages for all its brands and is building digital marketing programs in partnerships with Microsoft, Yahoo! and Amazon.com. The firm trims its product lineup as part of the ongoing stock-keeping unit-reduction program within its cost-savings initiative focused on increasing efficiency.

You may also be interested in...



Growing Social Media Use Justifies Higher Online Ad Spend

OTC firms should provide messaging across multiple channels, including social networks, Facebook, Twitter, Google+ and other platforms, says Google executive Michelle Schumaker. But traditional ads can link consumers to web sites as more watch TV on devices other than televisions, says Rick Mandler, of ABC.

Growing Social Media Use Justifies Higher Online Ad Spend

OTC firms should provide messaging across multiple channels, including social networks, Facebook, Twitter, Google+ and other platforms, says Google executive Michelle Schumaker. But traditional ads can link consumers to web sites as more watch TV on devices other than televisions, says Rick Mandler, of ABC.

Colgate "Unafraid" To Hike Prices To Offset Rising Costs

Colgate-Palmolive plans to raise prices on products across its portfolio and in all its regions to offset rising commodity costs.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS105607

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel